#None #Vienna #Atopic Dermatitis #Alopecia Areata #Rezpegaldesleukin

Groundbreaking Data on Rezpegaldesleukin at EADV Congress 2026

At the European Academy of Dermatology and Venereology (EADV) Congress held in Vienna, Austria, Nektar Therapeutics unveiled promising new findings on rezpegaldesleukin, a novel biologic designed to tackle autoimmune diseases like alopecia areata and atopic dermatitis. Presented by Dr. David Rosmarin, Chair of Dermatology at Indiana University, the data highlight significant advancements in long-term disease management for both conditions.

Long-term Durability in Alopecia Areata Patients

Rezpegaldesleukin's effectiveness was illustrated through initial findings from the Phase 2b REZOLVE-AA study. Remarkably, after one year of treatment, patients with severe alopecia areata showed not only sustained hair regrowth but also improved health metrics even after discontinuation of therapy. Specifically, 75% of patients maintained a SALT score of 20 or lower four months post-treatment, and 63% held this score at the six-month mark.

The study indicated that the drug encourages hair regrowth even after treatment cessation. Eighteen percent of patients achieved a SALT score of 10 or lower by the six-month follow-up, an increase from 7% at the end of the 52-week period, indicating that their condition continued to improve even after stopping treatment.

Expanding the Research Scope

Encouraged by these findings, Nektar Therapeutics is set to expand its research through the initiation of a third Phase 3 study within the global ZENITH AD program. This study will delve further into the efficacy of rezpegaldesleukin in patients with treatment-experienced atopic dermatitis, with initiation planned for early 2027.

Atopic Dermatitis Results and Future Prospects

In parallel, at the EADV Congress, findings from the REZOLVE-AD study were also shared by Dr. Thomas Bieber, underscoring the impressive durability of response and improvement in symptoms for patients with moderate-to-severe atopic dermatitis. The results indicated that both monthly and quarterly dosing regimens successfully provided a lasting reduction in disease severity indicators, such as EASI-75 and Itch NRS, with many patients achieving complete skin clearance. Notably, the 24 µg/kg dosage for both dosing intervals showed superior results, demonstrating the potential for less frequent dosing strategies moving forward.

As the research progresses, the hope is that rezpegaldesleukin will establish itself as a prominent treatment option for both alopecia areata and atopic dermatitis. Nektar's Chief Research and Development Officer, Jonathan Zalevsky, emphasized the necessity of ongoing studies to validate these findings further.

High Hopes for the Future

With its unique approach targeting T regulatory cells, rezpegaldesleukin represents a potential shift in the management of these chronic immune conditions. If these initial results hold true as the research progresses, it may soon become a game-changing treatment for patients who struggle with the severe impacts of autoimmune diseases. Patients and healthcare professionals alike eagerly await further insights during the upcoming conference call hosted by Nektar Therapeutics to discuss these groundbreaking findings further.

The momentum generated at EADV 2026 heralds a new age for treating autoimmune conditions, offering hope for effective, long-lasting relief to millions suffering worldwide.